

## 2017 Annual Conference BCOP Session Call for Proposals Topics

To be considered as a presenter, you must be board certified by the Board of Pharmaceutical Specialties (BPS), have clinical experience in the subject you are presenting, and have national or regional speaking experience.

These sessions will be presented in person at the HOPA Annual Meeting in March and the Fall Practice Management Program. As a presenter, you will develop your session as well as write 10 BPS-style questions for inclusion in the post-test. The meeting attendees can attend any of the eight sessions and must pass a post-test in order to receive credits toward BCOP recertification.

Proposals are currently being accepted for the following topics. Proposals submitted outside of the below list will be considered but are not guaranteed priority.

1. Head & Neck
  - a. Emphasis on molecular features (methylation profiles, mutated genes, microRNA expression) and drug-able targets
  - b. Emphasis on new therapies (vaccine data, AKT/mTOR/PI3K pathways) and SOC
2. Immunotherapy in Pediatric Oncology
  - a. Emphasis on tumor microenvironment, adoptive cell therapies, and antibody-based therapies for childhood cancers
3. Pharmacologic management of psycho-oncology concerns
  - a. Optimal/new SSRI/SNRIs, best approaches to anxiety management, drug-drug interactions, management of atypical antipsychotics while on chemo, etc.)
4. Treatment Considerations in Special Populations (pregnancy, amputees, rural populations, obesity, renal dysfunction)
5. Treatment approach for primary tumors of unknown origin
6. Immune thrombocytopenic purpura (ITP)
  - a. While addressing SOC in 2016, emphasis on experience with thrombopoietin receptor analogs in chronic ITP
  - b. Focus on adult treatment, but may mention pediatric tx approach
7. Updates in Management of Aplastic Anemia
8. Updates in Cancer Prevention and Early Detection
  - a. Ideas may include...Smoking Cessation, Skin Cancer Prevention, HPV Vaccination, new Dietary Guidelines
9. New Oncology Clinical Trial Designs: What Works?
  - a. Emphasis on basket, umbrella, and adaptive enrichment design strategies
  - b. Underlying statistical challenges and difficulty in reporting/understanding results
10. Adjuvant Treatment of Young Breast CA
  - a. Including survivorship considerations; Long-term chemo/XRT side effects